INBX
Inhibrx Biosciences, Inc.
There isn't enough reported data to score INBX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
INBX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INBX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INBX PE Valuation
INBX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INBX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect INBX's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
INBX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$8.88 | +$1.70 |
| Q1 2026 | -$8.39 | -107% |
| Q4 2025 | -$9.04 | -108% |
| Q3 2025 | -$10.02 | -108% |
| Q2 2025 | -$10.58 | -109% |
| Q1 2025 | $116.75 | +$122.10 |
| Q4 2024 | $118.11 | +$123.14 |
| Q3 2024 | $119.47 | +$123.72 |
INBX is still losing money, but less than at its worst: $8.88 per share over the past year, against $10.58 at its worst in mid-2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over INBX on earnings quality, reporting a profit while its opponent remains loss making.
INBX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $1.3M | +1200% |
| Q4 2024 | $100K | -94% |
| Q2 2024 | $100K | +233% |
| Q4 2023 | $1.6M | +496% |
| Q3 2023 | $119K | -57% |
| Q2 2023 | $30K | -96% |
| Q1 2023 | $17K | -98% |
| Q4 2022 | $274K | -90% |
INBX's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -2107% | +158791 points |
| Q4 2024 | -49928% | -44525 points |
| Q2 2024 | -160898% | -23101 points |
| Q4 2023 | -5403% | +7553 points |
| Q3 2023 | -38510% | -27718 points |
| Q2 2023 | -137797% | -132931 points |
| Q1 2023 | -257447% | -254274 points |
| Q4 2022 | -12956% | -12271 points |
INBX's operating margin was −2107% last quarter, up 36403 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
INBX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$29.9M | +$36K |
| Q1 2026 | -$38M | -$2.1M |
| Q4 2025 | -$30.1M | +$13.6M |
| Q3 2025 | -$33.8M | -$3.3M |
| Q1 2025 | -$35.9M | +$28.3M |
| Q4 2024 | -$43.7M | +$16.5M |
| Q3 2024 | -$30.5M | +$24.5M |
| Q1 2024 | -$64.2M | -$37.2M |
INBX has burned cash in almost every quarter: −$132M over the past year, against −$140M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over INBX on cash generation, producing positive trailing cash flow while its opponent burns cash.
INBX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +84K shares |
| 1 year | +1.3% | +201K shares |
| 3 years | -64% | -28M shares |
| 5 years | -58% | -22M shares |
INBX has 16M diluted shares, up 1.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over INBX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INBX Net Leverage
INBX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INBX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.6 | Neutral |
| Stochastic | 22.7 | Neutral |
INBX's weekly RSI is 48 (neutral) and its Stochastic is 23 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INBX PE vs Healthcare Sector
| Metric | INBX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INBX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INBX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $89.9 | 2.3% below |
| 20 week MA | $95.2 | 7.8% below |
| 50 week MA | $89.6 | 2.1% below |
| 100 week MA | $57.5 | 53% above |
LLY has stronger trend alignment. INBX is above 1 of 4 weekly averages versus LLY above 5 of 5.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
INBX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $34.1 | $15.0 | -56% |
| 2025 | $15.0 | $80.2 | +434% |
| 2026 YTD | $80.2 | $87.8 | +9.4% |
INBX's yearly returns have swung widely, from +434% in 2025 to −56% in 2024. It's up 9.4% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over INBX on returns for 2026, with the stronger performance.